Mylan, Inc. (NASDAQ:MYL) has confirmed plans to carry out a major acquisition in the year as it tries to expand its product portfolio across the industry. This is after seeing its first quarter revenue surge by 8% something that must have given the company the much needed financial backing. The company expects to complete a substantial transaction having being thought to be pursuing Swedish Pharmaceutical Company Meda, for quite some time. Mylan Inc. (NASDAQ:MYL) net profit margin is 9.00% and weekly performance is -2.90%. On last trading day company shares ended up $46.19. Analysts mean target price for the company is $60.47. Mylan Inc. (NASDAQ:MYL) distance from 50-day simple moving average (SMA50) is -6.82%.
Zacks cut shares of Auxilium Pharmaceuticals (NASDAQ:AUXL) from a neutral rating to an underperform rating in a research report sent to investors on Monday morning. Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL) shares advanced 0.10% in last trading session and ended the day on $19.81. AUXL gross Margin is 72.80% and its return on assets is -6.40%.Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL) quarterly performance is -29.68%.
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) reported Q1 EPS of ($0.25), $0.01 better than the analyst estimate of ($0.26). Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) shares moved down -1.92% in last trading session and was closed at $3.07, while trading in range of $3.05 – $3.23. Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) year to date (YTD) performance is -23.63%.
Oncolytics Biotech Inc. (USA) (NASDAQ:ONCY) announced that an abstract detailing early results from translational study looking at the intravenous administration of REOLYSIN(®) to patients with primary or metastatic brain tumors is now available on the ASCO Annual Meeting abstract website at http://abstracts.asco.org . The conference is being held from May 30(th) to June 3(rd), 2014 in Chicago, Illinois. Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY) ended the last trading day at $1.32. Company weekly volatility is calculated as 6.72% and price to cash ratio as 5.55.Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY) showed a positive weekly performance of 4.76%.
Cannabis Therapy Corp (OTCMKTS:CTCO) incurred net losses from operations of $336,736 and $862,374 for the three and six months ended March 31, 2014 and $3,584 and $7,423 for the three and six months ended March 31, 2013. On last trading day company shares ended up $0.950.